Pruritus Pipeline Analysis 2024: FDA Approvals and Emerging Therapies | Pfizer, Sanofi, Actavis, AbbVie, Astellas Pharma, Cara Therapeutics, EPI Health LLC, Galderma Laboratories LP, Ocera Therapeutics Inc.

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Pruritus pipeline constitutes 20+ key companies continuously working towards developing 25+ Pruritus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Pruritus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Pruritus Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pruritus Market.

Some of the key takeaways from the Pruritus Pipeline Report: https://www.delveinsight.com/sample-request/pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Pruritus treatment therapies with a considerable amount of success over the years.
• Pruritus companies working in the treatment market are Kamari Pharma Ltd, Mirum Pharmaceuticals, Haisco Pharmaceuticals, AB Science, Vanda Pharmaceuticals, Akron Children's Hospital, Xizang Haisco Pharmaceutical, GlaxoSmithKline, Escient Pharmaceuticals, Vifor Fresenius Medical Care, Qilu Pharmaceutical (Hainan), Cara Therapeutics, Inc., Keymed Biosciences Co.Ltd, Clexio Biosciences Ltd., Mirum Pharmaceuticals, Inc., DermBiont, Inc., Incyte Corporation, and others, are developing therapies for the Pruritus treatment
• Emerging Pruritus therapies in the different phases of clinical trials are- KM-001, Volixibat, HSK21542, Masitinib, Tradipitant, Dupilumab, HSK21542 tablet, Linerixibat, EP547, Difelikefalin Injection, QLG2198, difelikefalin, CM310, CLE-400, Volixibat, DBI-001 Gel, ruxolitinib cream, and others are expected to have a significant impact on the Pruritus market in the coming years.
• In March 2024, Mirum Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved LIVMARLI (maralixibat) oral solution for treating cholestatic pruritus in patients aged five and older with progressive familial intrahepatic cholestasis (PFIC).
• In June 2023, The U.S. Food and Drug Administration (FDA) approved Bylvay (odevixibat) for treating severe pruritus (itching) in patients aged 12 months and older with Alagille syndrome, a condition that impedes bile flow from the liver to the small intestine.

Pruritus Overview
Pruritus, commonly known as itching, is an uncomfortable sensation on the skin that provokes the urge to scratch. It can be a symptom of various conditions, ranging from minor irritations to serious underlying diseases.

Get a Free Sample PDF Report to know more about Pruritus Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Pruritus Drugs Under Different Phases of Clinical Development Include:
• KM-001: Kamari Pharma Ltd
• Volixibat: Mirum Pharmaceuticals
• HSK21542: Haisco Pharmaceuticals
• Masitinib: AB Science
• Tradipitant: Vanda Pharmaceuticals
• Dupilumab: Akron Children's Hospital
• HSK21542 tablet: Xizang Haisco Pharmaceutical
• Linerixibat: GlaxoSmithKline
• EP547: Escient Pharmaceuticals
• Difelikefalin Injection: Vifor Fresenius Medical Care
• QLG2198: Qilu Pharmaceutical (Hainan)
• difelikefalin: Cara Therapeutics, Inc.
• CM310: Keymed Biosciences Co.Ltd
• CLE-400: Clexio Biosciences Ltd.
• Volixibat: Mirum Pharmaceuticals, Inc.
• DBI-001 Gel: DermBiont, Inc.
• ruxolitinib cream: Incyte Corporation

Pruritus Route of Administration
Pruritus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Pruritus Molecule Type
Pruritus Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Pruritus Pipeline Therapeutics Assessment
• Pruritus Assessment by Product Type
• Pruritus By Stage and Product Type
• Pruritus Assessment by Route of Administration
• Pruritus By Stage and Route of Administration
• Pruritus Assessment by Molecule Type
• Pruritus by Stage and Molecule Type

DelveInsight's Pruritus Report covers around 25+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Pruritus product details are provided in the report. Download the Pruritus pipeline report to learn more about the emerging Pruritus therapies
https://www.delveinsight.com/sample-request/pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Pruritus Therapeutics Market include:
Key companies developing therapies for Pruritus are - Actavis, AbbVie Inc., Astellas Pharma Inc., Cara Therapeutics, EPI Health LLC, Galderma Laboratories LP, Ocera Therapeutics Inc., Pfizer Inc., Sanofi, Trevi Therapeutics, and others.

Pruritus Pipeline Analysis:
The Pruritus pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Pruritus with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pruritus Treatment.
• Pruritus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pruritus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pruritus market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pruritus drugs and therapies
https://www.delveinsight.com/sample-request/pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pruritus Pipeline Market Drivers
• Increasing Prevalence of Skin Disorders, Technological Advancements, are some of the important factors that are fueling the Pruritus Market.

Pruritus Pipeline Market Barriers
• However, High Development Costs, Generic Competition, and other factors are creating obstacles in the Pruritus Market growth.

Scope of Pruritus Pipeline Drug Insight
• Coverage: Global
• Key Pruritus Companies: Kamari Pharma Ltd, Mirum Pharmaceuticals, Haisco Pharmaceuticals, AB Science, Vanda Pharmaceuticals, Akron Children's Hospital, Xizang Haisco Pharmaceutical, GlaxoSmithKline, Escient Pharmaceuticals, Vifor Fresenius Medical Care, Qilu Pharmaceutical (Hainan), Cara Therapeutics, Inc., Keymed Biosciences Co.Ltd, Clexio Biosciences Ltd., Mirum Pharmaceuticals, Inc., DermBiont, Inc., Incyte Corporation, and others
• Key Pruritus Therapies: KM-001, Volixibat, HSK21542, Masitinib, Tradipitant, Dupilumab, HSK21542 tablet, Linerixibat, EP547, Difelikefalin Injection, QLG2198, difelikefalin, CM310, CLE-400, Volixibat, DBI-001 Gel, ruxolitinib cream, and others
• Pruritus Therapeutic Assessment: Pruritus current marketed and Pruritus emerging therapies
• Pruritus Market Dynamics: Pruritus market drivers and Pruritus market barriers

Request for Sample PDF Report for Pruritus Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Pruritus Report Introduction
2. Pruritus Executive Summary
3. Pruritus Overview
4. Pruritus- Analytical Perspective In-depth Commercial Assessment
5. Pruritus Pipeline Therapeutics
6. Pruritus Late Stage Products (Phase II/III)
7. Pruritus Mid Stage Products (Phase II)
8. Pruritus Early Stage Products (Phase I)
9. Pruritus Preclinical Stage Products
10. Pruritus Therapeutics Assessment
11. Pruritus Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Pruritus Key Companies
14. Pruritus Key Products
15. Pruritus Unmet Needs
16 . Pruritus Market Drivers and Barriers
17. Pruritus Future Perspectives and Conclusion
18. Pruritus Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Pruritus Market https://www.delveinsight.com/report-store/pruritus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Pruritus Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Pruritus Epidemiology https://www.delveinsight.com/report-store/pruritus-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Pruritus Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Generalized Myasthenia Gravis Market
https://www.delveinsight.com/report-store/generalized-myasthenia-gravis-gmg-market
DelveInsight's 'Generalized Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the Generalized Myasthenia Gravis, historical and forecasted epidemiology as well as the market trends in the United States, EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Glioblastoma Market
https://www.delveinsight.com/report-store/glioblastoma-market
DelveInsight's "Glioblastoma Market Insights, Epidemiology and Market Forecast- 2032" report delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Sickle Cell Disease Market
https://www.delveinsight.com/report-store/sickle-cell-disease-6mm-market
DelveInsight's "Sickle Cell Disease Market Insights, Epidemiology and Market Forecast- 2032" report delivers an in-depth understanding of the Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. Among the 6MM countries the Sickle cell disease market size was valued ~USD 650 million in 2023 and is expected to increase throughout the forecast period (2024-2034).

Holter Monitor Market
https://www.delveinsight.com/report-store/holter-monitor-market
The Global Holter Monitor market will grow at a CAGR of 6.13% during the forecast period from 2024 to 2030. The stellar growth observed in the market is primarily due to the growing burden of various cardiovascular disorders which leads to abnormal heart rhythm such as atrial fibrillation, and heart palpitations, among others that may require monitoring through Holter monitors.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.